1. Home
  2. BGSF vs SCLX Comparison

BGSF vs SCLX Comparison

Compare BGSF & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BGSF Inc.

BGSF

BGSF Inc.

N/A

Current Price

$5.51

Market Cap

64.0M

ML Signal

N/A

Logo Scilex Holding Company

SCLX

Scilex Holding Company

N/A

Current Price

$5.86

Market Cap

55.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BGSF
SCLX
Founded
2007
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.0M
55.1M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
BGSF
SCLX
Price
$5.51
$5.86
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.4K
59.5K
Earning Date
05-06-2026
04-10-2026
Dividend Yield
36.04%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$93,310,000.00
$30,253,000.00
Revenue This Year
$4.67
$122.52
Revenue Next Year
N/A
$186.30
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.26
$4.20
52 Week High
$8.20
$34.27

Technical Indicators

Market Signals
Indicator
BGSF
SCLX
Relative Strength Index (RSI) 45.00 33.68
Support Level $4.97 $5.48
Resistance Level $5.79 $7.77
Average True Range (ATR) 0.16 0.42
MACD -0.01 -0.08
Stochastic Oscillator 17.13 13.24

Price Performance

Historical Comparison
BGSF
SCLX

About BGSF BGSF Inc.

BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. The company operates in one segment of Property Management, which includes centralized support services through executive, marketing, human resources, information technology, accounting, treasury, and billing operations.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: